| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | ROCE | Debt / equity | Free cash flow | Beta |
|---|---|---|---|---|---|---|---|---|---|---|
| ₹318 cr | ₹138 cr | ₹-9 cr | — | -2.50 | 3.44 | -10.2% | -6.0% | 0.52 | ₹-6 cr | 1.14 |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Jun 2026 | 42 | 2 | 0.57 | +128.0% | +28.1% | 4.8% |
| Mar 2026 | 28 | -8 | -2.13 | -534.7% | -16.2% | -28.8% |
| Dec 2025 | 31 | -0 | 0.00 | -100.0% | -9.1% | -0.5% |
| Sep 2025 | 37 | -3 | -0.94 | -262.1% | -10.9% | -8.8% |
| Jun 2025 | 33 | 1 | 0.25 | — | — | 3.0% |
| Mar 2025 | 33 | 2 | 0.49 | — | — | 6.1% |
| Dec 2024 | 34 | 3 | 0.75 | — | — | 8.0% |
| Sep 2024 | 41 | 2 | 0.58 | — | — | 5.1% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | ✓ Pass |
| EPS growth positive and accelerating over 3 consecutive quarters | ✗ Fail |
| Sales up 25%+, or sales growth positive and accelerating | ✓ Pass |
| Annual EPS up 25%+ in each of the last 2 years (3 full years needed) | — Not assessable |
| Net margin above the same quarter last year | ✓ Pass |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Minervini | ✓ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✓ 200-day rising for a month ✓ 50-day above the 150- and 200-day ✓ Close above the 50-day ✓ At least 25% above the 52-week low · low 44.95 ✓ Within 25% of the 52-week high · high 93.64 ✓ RS percentile 70 or more · RS 79 Minervini's trend template - the gate the scanner applies. | 8/8 | Pass |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 2 - advancing | |
| CAN SLIM | ✓ C latest quarter EPS up 25%+, with sales up 25%+ or accelerating — A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✓ N (proxy) near the 52-week high - within 15% · high 93.64 ✓ S (proxy) more volume on up days than down days (50 sessions) · 2.30x ✗ L RS percentile 80 or more · RS 79 — I (proxy) FII + DII holding trend · not yet collected for this stock ✓ M (proxy) market in an uptrend, 40%+ of stocks above their 200-day - shared, not counted · breadth 51% William O'Neil's growth-leader checklist, as a checklist score: the six stock letters counted equally, though O'Neil read them together. M is the market condition, shown but not counted. N, S, I and M are proxies. | 3/4 | Average |
| Darvas | ✗ New 52-week high in the last 120 sessions Darvas needs a new 52-week high to start a box. | 10/100 | No box |
| Turtle | ✓ Close above the prior 55-session high · 88.00 ✓ Close above the prior 20-session high · 87.79 ✗ Close below the prior 20-session low (also a Turtle exit level) · 74.06 Turtle-inspired long breakout: the Turtle traders' entry channels only - no exits, stops or position sizing. | Breakout (55-day) | |
| Graham | Needs positive earnings and book value. | Not assessable | |
| Piotroski | ✗ Profitable (ROA > 0, on beginning-of-year assets) ✓ Operating cash flow positive — ROA rising · needs three years ✓ Cash flow above net profit (earnings quality) — Long-term debt / average assets lower · needs three years ✗ Current ratio higher · 1.17 ✓ No new equity issued — Gross margin higher · not assessed - gross profit not filed here — Asset turnover higher (sales / beginning assets) · needs three years Piotroski F-score (adapted), FY 2025 -> 2026: 3 of 9 passed, 4 not assessed. Piotroski applied it to value stocks; here it is shown for all non-financial companies. | 3/9 | Weak |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LYKALABS this stock | +0.3 | +29.4 | +42.9 | +2.4 | -22.0 | -26.9 | — | 3.44 | -10.2 | -6.0 | -5.95 | 0.52 | — | 318 | 138 | -9 | -2.5 | 1.14 |
| BLISSGVS | +0.7 | +26.1 | +136.4 | +301.9 | +405.5 | +549.5 | 43.1 | 5.41 | 11.5 | 16.8 | 9.65 | 0.00 | 24.8 | 6,979 | 1,074 | 166 | 15.2 | 0.90 |
| INDSWFTLAB | -7.6 | +6.0 | +147.9 | +233.3 | +252.7 | +338.4 | 34.0 | 1.96 | 3.2 | 3.9 | 2.66 | 0.01 | 19.8 | 2,886 | 753 | 84 | 9.8 | 0.60 |
| VENUSREM | -7.6 | -15.4 | +67.3 | +174.9 | +341.6 | — | 16.8 | 2.89 | 16.8 | 21.9 | 13.10 | 0.00 | 11.0 | 2,039 | 837 | 122 | 91.0 | 0.87 |
| BAFNAPH | +2.5 | +83.5 | +249.6 | +161.1 | +492.4 | +229.5 | 97.3 | 10.84 | 12.3 | 11.9 | 6.76 | 0.36 | 53.2 | 1,119 | 155 | 12 | 4.9 | 0.37 |
| SHILPAMED | -2.2 | +13.3 | +91.7 | +144.7 | +388.1 | +224.5 | 53.7 | 6.51 | 9.8 | 11.4 | 6.94 | 0.24 | 33.8 | 17,942 | 1,842 | 332 | 17.1 | 0.74 |
| ACUTAAS | +23.0 | +23.3 | +44.4 | +130.7 | +624.3 | +690.7 | 73.5 | 17.38 | 24.0 | 31.7 | 20.17 | 0.00 | 49.6 | 32,281 | 1,592 | 439 | 53.6 | 0.68 |
| LAURUSLABS | +13.5 | +29.2 | +76.6 | +128.8 | +532.1 | +383.1 | 94.2 | 20.84 | 18.2 | 17.9 | 8.97 | 0.41 | 66.8 | 1.26L | 7,822 | 1,332 | 24.8 | 0.66 |
| RUBICON | +11.6 | -6.4 | +75.2 | +126.9 | — | — | 85.4 | 19.68 | 22.6 | — | — | 0.28 | 54.2 | 27,874 | 2,100 | 325 | 19.7 | 0.34 |
| IOLCP | -2.0 | +18.3 | +80.0 | +99.4 | +124.8 | +99.1 | 27.6 | 2.91 | 7.9 | 10.7 | 5.54 | 0.10 | 15.7 | 5,599 | 2,751 | 203 | 6.9 | 1.04 |
| SAILIFE | +26.1 | +23.7 | +60.6 | +99.1 | — | — | 98.5 | 13.84 | 15.1 | 20.9 | 10.28 | 0.17 | 53.5 | 37,205 | 2,372 | 376 | 17.8 | 0.82 |
← All NSE stocks · More Pharma stocks